Health, Life Sciences & Care Systems
The reorganisation of how care gets delivered.
Latest: England's nursing supply fell from both overseas and domestic sources in 2025-26. Overseas-educated joiners fell 47% and UK-educated 4.9% as vacancies shrank, while policy needs a bigger domestic...
Treatment Got Cheaper. Care Became the Bottleneck.
Over this cycle, the binding constraint moved from making and pricing medicines to paying for and staffing care. Nine weeks ago the central question was whether medicine had become industrial policy, settled by tariffs and pricing deals. It had, and the deals spread.
Cheaper Pills, Scarcer Care
Medicines are becoming cheaper and easier to get, while care and the insurance that pays for it are becoming scarcer.
England's Nursing Supply Fell From Both Overseas and Domestic Sources at Once
England's nursing supply fell from both overseas and domestic sources in 2025-26. Overseas-educated joiners fell 47% and UK-educated 4.9% as vacancies shrank, while policy needs a bigger domestic...
Posture: PrepareState Verification Choices, Not Work Status, Will Decide Medicaid Losses
State administrative design, not work status, is what determines who loses Medicaid coverage under the new work requirement.
Posture: PrepareMedicare Reprices the Hospital Outpatient Premium by Service Family, and From 2028 Site by Site
Medicare is withdrawing the hospital outpatient payment premium one service family at a time rather than in a single cut.
Posture: PrepareAmerica's Nuclear Regulator Treats Oncology Capacity as a Licensing Problem and Deregulates the Authorised User
The ceiling on radioligand cancer therapy is a nuclear licence, not an isotope shortage. The US Nuclear Regulatory Commission proposed on 27 July 2026 to strip prescriptive training hours and...
Posture: PrepareEbola spreads to 60 health zones as pathogen access goes bilateral
Fourth Change Tracker on Health, Life Sciences and Care Systems. Ten signals: 6 Accelerating (Bundibugyo Ebola emergency, global health financing retrenchment, pathogen access as bilateral leverage...
China's Premium Drug Channel Is Being Underwritten by the Drugmakers
China's state-curated premium drug list has no payer, so its premium price is being underwritten by the drugmakers themselves.
Posture: PrepareThe Defined-Contribution Crossover: Employers Reach for the Individual Market as It Shrinks
US employers are converting health coverage from a defined benefit into a fixed contribution just as the individual market they would hand workers to contracts.
Posture: PrepareOut of Order: Disclosure Arrived Before the Denominators, Automation Before the Oversight Rules
The US prior-authorisation accountability instruments are arriving in the wrong order. Disclosure landed without denominators, human-review rules for automated denial are still only recommended, and...
Posture: PrepareThe Price of the Dataset: African Governments Are Turning Down Health Aid Over Data Terms
The consideration in the bilateral deals replacing US health aid is the national health dataset, not only the money.
Posture: PrepareEbola response trails transmission while US immunisation cover keeps thinning
Third Change Tracker on Health, Life Sciences and Care Systems. Ten signals: 5 Accelerating (Bundibugyo Ebola emergency, US measles elimination at risk, US vaccine-policy disruption, US pharma...
Out of Scope by Design: Clinical AI Accountability Lands on the Clinician
Accountability for clinical AI has been relocated from the product to the practitioner. The EU deferred its high-risk rules and the MHRA placed AI scribes outside device regulation, both on the...
Posture: PrepareThe Cure Was the Decoy
The breakthroughs took the headlines while the binding constraint on medicine migrated to the layers a molecule cannot reach: price, patent, payer track, supply origin and the global health commons...
The Summer Medicine Chose Sides
This was the summer medicine chose sides. Within a few months the US put a 100 percent tariff on patented drugs and tied it to price, seventeen manufacturers signed pricing deals, the EU passed a...
Rationing by Assessment: How the Eligibility Threshold Became Long-Term Care's Main Cost Lever
Long-term care rationing has moved from the benefit schedule into the eligibility assessment. Germany's draft care law books its largest saving from recalibrating the assessment instrument, and...
Posture: PrepareThe Linkage Fight: Why an Unfinished WHO Annex Now Carries the Weight of the Treaty
An unfinished technical annex now gates the WHO Pandemic Agreement's entry into force. The unresolved question is whether access to pathogens and sequence data stays legally tied to benefit-sharing...
Posture: PrepareOne Country, Many Vaccine Schedules: America's Immunization Standard Splintered Into a Non-Federal Patchwork
Beneath the fight over the US administration's vaccine changes, the decades-long single national immunization standard has splintered: medical societies and 28 states now issue their own schedules...
Posture: PrepareThe 100/20/0 Menu: How US Pharma Tariffs Force Onshoring and Price Cuts, Company by Company
Beneath the 'pharma tariffs raise prices' headline, the April 2026 Section 232 duty is a tiered coercion menu (100% default; 20% with a Commerce onshoring plan; 0% to 2029 only with an HHS...
Posture: PrepareUS pharma tariffs near enforcement; global health financing retreats
Second Change Tracker on Health, Life Sciences and Care Systems. Ten signals: 4 Accelerating (US pharma tariffs and MFN pricing, global health financing retrenchment, US vaccine-policy disruption...
Approved on Mechanism, Not Trials: The FDA's Plausible-Mechanism Reset for Bespoke Gene Therapies
Beneath the consensus that gene therapy is failing commercially, the FDA is rebuilding the approval model for individualized genetic medicines, letting variant-specific gene editors clear as a...
Posture: PrepareAfter the Market Failure: How 'Subscription' Payments for Antibiotics Are Crossing From Pilot to Policy
Beneath the consensus that antibiotic R&D is a permanent market failure, a delinked 'subscription' pull-payment standard is consolidating across the UK, EU and US at once in 2026: the UK model...
Posture: PrepareTwo-Track Obesity Care: How GLP-1 Access Split by Payer Just as the Pills Arrived
Beneath the consensus that GLP-1 weight-loss drugs are becoming universal, US obesity-drug access is splitting by payer into a time-limited, ring-fenced Medicare track and a manufacturer cash market...
Posture: PrepareThe Borrowed Pipeline: Western Pharma's Dependence on China-Originated Drugs Collides With Decoupling
Western pharma's future pipeline is becoming dependent on China-originated molecules even as the US and Europe still appear to lead biopharma innovation.
Posture: PrepareTariff and pricing shocks accelerate; pandemic governance stalls
Inaugural cycle. The momentum sits in policy and trade: a US Section 232 pharmaceutical tariff and most-favored-nation pricing regime, the EU Critical Medicines Act and a Medicare GLP-1 access push...
When the Cure Outruns the Checkbook: The Gene-Therapy Payment Model Is Being Rebuilt Around Outcomes
The one-time-cure gene-therapy business model is failing even where the science works, as systems built for chronic pay-over-time care cannot finance multimillion-dollar cures.
Posture: PrepareToo Much Cure, Not Enough Care
capability AI, biotech, DTx capacity clinical workforce GAP reimbursement + regulation bridge The cycle's central tension: capability is rising, capacity is falling, and the institutional bridges (reimbursement architectures, regulatory frameworks) are racing to close the gap.
Diagnosed, Then What? Alzheimer's Blood Tests Are Outrunning Treatment and Care Capacity
Scalable primary-care Alzheimer's blood tests are moving diagnosis out of specialist gatekeeping faster than health systems can confirm, treat or support the patients identified, opening a...
Posture: PrepareExporting the Price Fight: How US Drug-Pricing Reform Is Quietly Repricing Medicines Worldwide
US Most-Favored-Nation drug pricing is restructuring global pharmaceutical pricing through its international reference mechanism.
Posture: PrepareThe 2026 Patent Geography Split
Beneath the headline GLP-1 boom, semaglutide patent expiry across India, Brazil, China, Canada and Türkiye in 2026 is creating a two-tier global obesity-drug market: restructuring pricing power...
The MCED Coverage-Evidence Gap
Beneath the headline launch of multi-cancer blood tests, the Sewell Act enacted February 2026 has authorised Medicare coverage of MCED screening from 2028 even as the landmark NHS-Galleri trial...
The Homology Trap
As the United States moves to make DNA synthesis screening mandatory, the screening method being written into law matches orders against known-pathogen lists, a paradigm AI protein-design tools have...